Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 16/20 | 0.43 |
| ▸ | TAB1 | Q15750 | 16/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661649 | 1.00 | MAP3K7 (0.43) | MAP3K7TAB1AURKBRETKDR | |
| SCHEMBL660733 | 0.92 | MAP3K7 (0.47) | MAP3K7TAB1AURKBRETKDR | |
| SCHEMBL660734 | 0.92 | MAP3K7 (0.47) | MAP3K7TAB1AURKBRETKDR | |
| SCHEMBL658919 | 0.83 | MAP3K7 (0.49) | MAP3K7TAB1MAP4K3 | |
| SCHEMBL661045 | 0.83 | MAP3K7 (0.49) | MAP3K7TAB1MAP4K3 | |
| SCHEMBL658408 | 0.79 | MAP3K7 (0.49) | MAP3K7TAB1 | |
| SCHEMBL658407 | 0.75 | MAP3K7 (0.43) | MAP3K7TAB1 | |
| SCHEMBL660206 | 0.75 | MAP3K7 (0.59) | MAP3K7TAB1MAP4K3 | |
| SCHEMBL660205 | 0.75 | MAP3K7 (0.59) | MAP3K7TAB1MAP4K3 | |
| SCHEMBL660410 | 0.73 | MET (0.40) | MAP3K7TAB1METMAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | MAP3K7 5/4885TAB1 4/4885AURKB 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.